Lymphopenia and clinical outcomes in patients with residual nodal disease after neoadjuvant chemotherapy for breast cancer
Menée sur 99 patientes atteintes d'un cancer du sein et présentant un envahissement ganglionnaire résiduel après une chimiothérapie néoadjuvante (durée médiane de suivi : 44 mois ; âge médian : 48 ans), cette étude évalue l'association entre la survenue d'une lymphopénie après le traitement et les résultats cliniques ainsi que la survie globale
Background : Patients with residual nodal disease after neoadjuvant chemotherapy for breast cancer have a poor prognosis. We wanted to evaluate whether lymphopenia after treatment for breast cancer impacted clinical outcomes.
Materials and methods : We assessed 99 patients with node-positive disease after neoadjuvant chemotherapy. Absolute lymphocyte count was recorded 1 year after radiation. Dates of local, regional, and distant failure were recorded. Time to event outcomes were evaluated using Kaplan–Meier analysis. Multivariable analysis determined factors predictive for overall survival.
Results : Median follow-up was 44 months (range 3–150). Median age was 48 years (range 23–79). Twenty-six patients (26%) had lymphopenia 1 year after RT. Patients with lymphopenia had a greater incidence of regional (p = 0.03) and distant failure (p = 0.009) compared to those with normal lymphocyte counts and had a 6.05 greater risk of death (p = 0.0002).
Conclusions : In patients with residual nodal disease after neoadjuvant chemotherapy, lymphopenia after breast cancer treatment was associated with overall survival. The relationship between lymphopenia and breast cancer outcomes warrants further investigation.
Cancer Causes & Control , article en libre accès, 2020